Table 2.
Selected combination studies with BCR inhibitors
TBD indicates to be determined; CLL, chronic lymphocytic leukemia; and NHL, non-Hodgkin lymphoma.
*NCT codes indicate ongoing studies with data available at www.clinicaltrials.gov.
Selected combination studies with BCR inhibitors
TBD indicates to be determined; CLL, chronic lymphocytic leukemia; and NHL, non-Hodgkin lymphoma.
*NCT codes indicate ongoing studies with data available at www.clinicaltrials.gov.
